VERTEX PHARMACEUTICALS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 429.9 USD | +1.69% |
|
+6.81% | +5.66% |
| 05-10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
| 05-07 | FOMO is Back |  |
Presenter SpeechMichael Partridge (Executives)Welcome to the Vertex Third Quarter 2018 Confere...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-05-15
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8
USD
Average target price
462.1
USD
Spread / Average Target
+9.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B | |
| +288.77% | 8.12B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated, Q3 2018 Earnings Call, Oct 24, 2018
